Firebrick Pharma 2022 Investor Presentation - Nasodine IPO

Firebrick Pharma is an Australian pharmaceutical company developing Nasodine, a first-in-class nasal spray using povidone-iodine to treat and prevent common colds and COVID-19. The company has completed Phase 1-3 trials with patent protection through 2034/2035 and is pursuing regulatory approval with manufacturing ready.